By G HossainPosted on January 21, 2026Posted in Pharmaceutical & Bio Science, UncategorizedTagged bio science career, blogs, business career news, career tips, job blog, job news, RJF Pharmaceutical Jobs After winning a surprise approval for its hereditary angioedema drug Ekterly, KalVista is confident the oral offering will capture the lion’s share of the market for on-demand use. JPM26: KalVista’s HAE Win Is a ‘Tale of Two Markets’ Post navigation JPM26 Recap, Novo’s Oral Wegovy Soars as Lilly’s Orforglipron Is Delayed, IPOs ReturnJPM26: Filling C-Suites, Union Square—and Elevators—With Pink